Just saw this - SeaStar Medical actually finished enrolling all 50 patients for their SAVE Registry studying QUELIMMUNE in kids with AKI from sepsis. Pretty significant since this was an FDA requirement post-approval. The therapy got approved under humanitarian exemption last year, which is pretty rare for pediatric conditions like acute kidney injury.

What caught my attention is the early data they published in Pediatric Nephrology looks solid - 77% survival rate and most survivors didn't need dialysis. That's actually impressive for such a critical patient population dealing with AKI complications from septic conditions.

They're saying hospitals have been interested but faced some operational challenges getting set up for the registry. Now that enrollment's done, SeaStar expects more adoption as institutions finish their onboarding. Also running a bigger adult trial (NEUTRALIZE-AKI) for AKI patients on continuous renal replacement therapy, so the platform's expanding beyond pediatrics.

Stock's been all over the place - traded between $2.20 and $23.70 over the past year, currently sitting at $2.64, up about 5.7%. Interesting play if you're watching the biotech/medical device space.